Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study

Open access

Abstract

OBJECTIVE: Venous thromboembolism (VTE) is associated with almost 300,000 deaths per year in the United States. Novel oral anticoagulants (NOACs) offer an alternative to warfarin-based therapy without monitoring requirements and with fewer drug and food interactions. Edoxaban, a direct Xa inhibitor, is approved by the Food and Drug Administration (FDA), based upon results of the Hokusai-VTE Phase 3 trial. The trial demonstrated that edoxaban administered once daily after initial treatment with heparin was non-inferior in reducing the risk of VTE recurrence and caused significantly less major and clinically relevant non-major (CRNM) bleeding compared to warfarin. The objective of this study was to evaluate the cost-effectiveness of edoxaban versus warfarin for the treatment of adults with VTE. METHODS: A cost-effectiveness model was developed using patient-level data from the Hokusai-VTE trial, clinical event costs from real-world databases, and drug acquisition costs for warfarin of $0.36 and edoxaban of $9.24 per tablet. RESULTS: From a U.S. health-care delivery system perspective, the incremental cost-effectiveness ratio (ICER) was $22,057 per quality adjusted life year (QALY) gained. Probabilistic sensitivity analysis showed that edoxaban had an ICER <$50,000 per QALY gained relative to warfarin in 67% of model simulations. The result was robust to variation in key model parameters including the cost and disutility of warfarin monitoring. CONCLUSION: Despite its higher drug acquisition cost, edoxaban is a cost-effective alternative to warfarin for the treatment of VTE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21548331.2015.1099412

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Murphy SL, 2013, Deaths: final data for 2010. National vital statistics reports, 61

Cited by

See all 28

Metadata

Authors
Preblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z.
Affiliations
  • Daiichi Sankyo (United States) (US)
  • University of California Davis Medical Center (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Kwong, W. Jacqueline
Venue
Hospital Practice
Published
2015-11-07
Volume
43
Issue
5
Pages
249-257
ISSN
  • 0018-5809 (ISSN-L)
  • 2154-8331
  • 2377-1003
OpenAlex
W2195501587
Cited by
28
References
40
Citations by year
2024: 1 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 3
FWCI
3.37
Type
journal article
Language
en
Open access
Locations
  • Hospital Practice (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Daiichi-Sankyo
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
edoxaban, venous thromboembolism, cost-effectiveness, warfarin, direct oral anticoagulants, bleeding risk, quality-adjusted life years
MeSH terms
Adult, Anticoagulants, Cost-Benefit Analysis, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pyridines, Thiazoles, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Venous Thromboembolism, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. https://app.cochat.ai/papers/10.1080/21548331.2015.1099412
The paper
Preblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z. (2015). Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. Hospital Practice. https://doi.org/10.1080/21548331.2015.1099412

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.